The evolution and impact of therapy in multiple myeloma

[1]  D. Horsman,et al.  Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. , 2009, Blood.

[2]  J. Reynolds,et al.  Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Fanin,et al.  Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. , 2009, Blood.

[4]  P. Hari,et al.  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. , 2009, Blood.

[5]  D. Esseltine,et al.  Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. , 2008 .

[6]  M. Baccarani,et al.  Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma , 2008 .

[7]  J. S. San Miguel,et al.  A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. , 2008, Blood.

[8]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[9]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[10]  M. Williams,et al.  Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi , 2008 .

[11]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[12]  P. Richardson,et al.  A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma , 2008, Therapeutics and clinical risk management.

[13]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[14]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[15]  M. Baccarani,et al.  Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient‐specific tumour idiotype protein or idiotype (VDJ)‐derived class I‐restricted peptides , 2007, British journal of haematology.

[16]  B. Pégourié,et al.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.

[17]  B. Barlogie,et al.  Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 , 2007, British journal of haematology.

[18]  M. Baccarani,et al.  Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Munshi,et al.  New drugs for myeloma. , 2007, The oncologist.

[20]  Diane Warren,et al.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.

[21]  Serge Leyvraz,et al.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.

[22]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[23]  A Palumbo,et al.  Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Vincenzo Callea,et al.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.

[25]  John Crowley,et al.  Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.

[26]  Rafael Fonseca,et al.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Esseltine,et al.  Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. , 2005, Blood.

[28]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[29]  D. Esseltine,et al.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma , 2004, British journal of haematology.

[30]  R. Bataille,et al.  Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.

[31]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[32]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[33]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[34]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[35]  B. Hillner,et al.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[37]  J. Crowley,et al.  Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. , 2002, Blood.

[38]  G. Morgan,et al.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.

[39]  R. Kyle.  Multiple myeloma: an odyssey of discovery , 2000, British journal of haematology.

[40]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[41]  J. Crowley,et al.  Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Marcus,et al.  Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. , 1996, Blood.

[43]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[44]  H. Nieuwenhuis,et al.  Graft-versus-myeloma effect in two cases , 1996, The Lancet.

[45]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[46]  D. Ribatti,et al.  Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44 , 1995, American journal of hematology.

[47]  D. Ribatti,et al.  Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.

[48]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Dimopoulos,et al.  Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. , 1993, Blood.

[50]  B. Barlogie,et al.  Primary dexamethasone treatment of multiple myeloma. , 1992, Blood.

[51]  A. Newland,et al.  INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA , 1989, The Lancet.

[52]  M. Slevin,et al.  Multiple myeloma treated with high dose intravenous melphalan , 1987, British journal of haematology.

[53]  R. Kyle,et al.  Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Zander,et al.  High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. , 1986, Blood.

[55]  T. Mcelwain,et al.  HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA , 1983, The Lancet.

[56]  D. Dalley,et al.  TRIPLE DRUG CHEMOTHERAPY FOR ADVANCED OVARIAN CARCINOMA COMPARATIVE STUDY OF TWO REGIMENS , 1981, Medical Journal of Australia.

[57]  R. Alexanian.  Plasma cell neoplasms , 1978, CA: a cancer journal for clinicians.

[58]  T. Landberg,et al.  [Combination chemotherapy in Hodgkin's disease]. , 1974, Lakartidningen.

[59]  B. Clarkson,et al.  Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU , 1974, Cancer.

[60]  H. Wilson,et al.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.

[61]  P. Sheehe,et al.  Melphalan in multiple myeloma. , 1967, Blood.

[62]  S. Salmon,et al.  Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. , 1967, Cancer chemotherapy reports.

[63]  L. Lasagna,et al.  A controlled trial of urethane treatment in multiple myeloma. , 1966, Blood.

[64]  H. Wilson,et al.  MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS. , 1964, JAMA.

[65]  M. Call,et al.  PROLONGED REMISSION OF MYELOMA WITH CYCLOPHOSPHAMIDE. , 1964, Archives of Internal Medicine.

[66]  D. Bergsagel,et al.  Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). , 1962, Cancer chemotherapy reports.

[67]  J. Gally,et al.  The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins. , 1962 .

[68]  M. Re.  A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. , 1962 .

[69]  E. Freireich,et al.  A comparative study of two regimens of combination chemotherapy in acute leukemia. , 1958, Blood.

[70]  N. Perevodchikova,et al.  CLINICAL EXPERIENCES WITH SARCOLYSIN IN NEOPLASTIC DISEASES , 1958, Annals of the New York Academy of Sciences.

[71]  R. Rundles,et al.  Multiple myeloma. III. Effect of urethane therapy on plasma cell growth, abnormal serum protein components and Bence Jones proteinuria. , 1950, The Journal of clinical investigation.

[72]  C. Weder.  Urethane in the treatment of multiple myeloma. , 1950, Canadian Medical Association journal.

[73]  H. Bencejones.  Papers ON CHEMICAL PATHOLOGY; Prefaced by the Gulstonian Lectures, read at the Royal College of Physicians, 1846 , 1847 .

[74]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[75]  P. Sonneveld,et al.  Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials , 2007, Leukemia.

[76]  A. Dalgleish,et al.  Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.

[77]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[78]  J. Esteve,et al.  Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. , 2001, The hematology journal : the official journal of the European Haematology Association.

[79]  Mike Clarke,et al.  Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  E. Greenspan,et al.  Combination chemotherapy of advanced ovarian carcinoma with the antimetabolite, methotrexate, and the alkylating agent, thioTEPA. , 1962, Journal of the Mount Sinai Hospital, New York.

[81]  R. Mass.  A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. , 1962, Cancer chemotherapy reports.

[82]  J. Waldenstrom.  Studies on conditions associated with disturbed gamma globulin formation (gammopathies). , 1960, Harvey lectures.

[83]  S. Solly.  Remarks on the pathology of mollities ossium; with cases. , 1844, Medico-chirurgical transactions.

[84]  H. Jones.  On a New Substance Occurring in the Urine of a Patient with Mollities Ossium. , 1843 .